Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Maximilian Lobmeyer"'
Autor:
Sebastian Frechen, Ibrahim Ince, André Dallmann, Michael Gerisch, Natalia A. Jungmann, Corina Becker, Maximilian Lobmeyer, Maria E. Trujillo, Shiyao Xu, Rolf Burghaus, Michaela Meyer
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 1, Pp 79-92 (2024)
Abstract Vericiguat (Verquvo; US: Merck, other countries: Bayer) is a novel drug for the treatment of chronic heart failure. Preclinical studies have demonstrated that the primary route of metabolism for vericiguat is glucuronidation, mainly catalyze
Externí odkaz:
https://doaj.org/article/c66c5343a35c4c0781974a7a44021a40
Autor:
Corina Becker, Michael Boettcher, Uwe Muenster, Stephanie Loewen, Maximilian Lobmeyer, Wolfgang Mueck
Publikováno v:
AAPS Open, Vol 8, Iss 1, Pp 1-14 (2022)
Abstract Objective This article describes in vitro and in vivo studies that aimed to further characterize the biopharmaceutical properties and pharmacokinetic (PK) profile of vericiguat and to guide dosing recommendations. Methods Five open-label, ph
Externí odkaz:
https://doaj.org/article/4892723d0c0347558a185457f4716204
Autor:
Stefan Willmann, Eleonora Marostica, Nelleke Snelder, Alexander Solms, Markus Jensen, Maximilian Lobmeyer, Anthonie W. A. Lensing, Claudette Bethune, Erin Morgan, Rosie Z. Yu, Yanfeng Wang, Shiangtung W. Jung, Richard Geary, Sanjay Bhanot
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 890-901 (2021)
Abstract IONIS‐FXIRX (BAY2306001) is an antisense oligonucleotide that inhibits the synthesis of coagulation factor XI (FXI) and has been investigated in healthy volunteers and patients with end‐stage renal disease (ESRD). FXI‐LICA (BAY2976217)
Externí odkaz:
https://doaj.org/article/a0f07a9e368749df85e58f6529f928d9
Autor:
Sanjay Bhanot, Eleonora Marostica, Maximilian Lobmeyer, Nelleke Snelder, Erin E. Morgan, Anthonie W. A. Lensing, Richard S. Geary, Markus Jensen, Shiangtung W. Jung, Yanfeng Wang, Rosie Z. Yu, Stefan Willmann, Claudette Bethune, Alexander Solms
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 890-901 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
IONIS‐FXIRX (BAY2306001) is an antisense oligonucleotide that inhibits the synthesis of coagulation factor XI (FXI) and has been investigated in healthy volunteers and patients with end‐stage renal disease (ESRD). FXI‐LICA (BAY2976217) shares t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c833bb12274e461ae57144f261c44b4
https://doaj.org/article/a0f07a9e368749df85e58f6529f928d9
https://doaj.org/article/a0f07a9e368749df85e58f6529f928d9
Autor:
Wolfgang Mueck, A.O Aliprantis, Maximilian Lobmeyer, M Meyer, Michael Boettcher, Corina Becker, M Trujillo
Publikováno v:
European Heart Journal. 41
Introduction The Phase III VICTORIA study (NCT02861534), which evaluated vericiguat vs placebo in patients with worsening chronic heart failure (WCHF) with ejection fraction Purpose A comprehensive clinical pharmacological programme of 28 Phase I tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d22ef17793b1fdcfa3f44bc7f6812c8
https://doi.org/10.1093/ehjci/ehaa946.3328
https://doi.org/10.1093/ehjci/ehaa946.3328
Autor:
Michael Gerisch, Sebastian Frechen, Maximilian Lobmeyer, Rolf Burghaus, Ibrahim Ince, S Xu, N Jungmann, M Trujillo, Michaela Meyer, André Dallmann, Corina Becker
Publikováno v:
European Heart Journal. 41
Introduction Vericiguat is a once daily, novel oral stimulator of soluble guanylate cyclase (sGC) that showed clinical benefit in the Phase III VICTORIA study in heart failure patients with reduced ejection fraction (HFrEF, NCT02861534). Nonclinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::23f674e77a26cb124c212706a399dfb7
https://doi.org/10.1093/ehjci/ehaa946.3329
https://doi.org/10.1093/ehjci/ehaa946.3329
Autor:
Martin Radtke, Corina Becker, Nina Besche, Mireille Gerrits, Julia Lemmen, Dirk Thomas, Michael Boettcher, Wolfgang Mueck, Michael Gerisch, Maximilian Lobmeyer
Publikováno v:
Clinical Pharmacokinetics
Background Vericiguat is a stimulator of soluble guanylate cyclase currently under investigation as a first-in-class therapy for worsening chronic heart failure (NCT02861534). Patients with heart failure often require polypharmacy because of comorbid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4868a371ea6899ea09d0fd298497128c
https://pubmed.ncbi.nlm.nih.gov/32458378
https://pubmed.ncbi.nlm.nih.gov/32458378